Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUL-138 is a small molecule 6-chromanol derivative inspired by the metabolic plasticity of hibernating animals. It functions as a mitochondrial bioenergetics enhancer by supporting the activity of Complex I (NADH dehydrogenase) and Complex IV (cytochrome c oxidase) within the electron transport chain. This mechanism promotes ATP production and reduces the generation of reactive oxygen species (ROS) without affecting basal mitochondrial membrane potential. Preclinical studies in Alzheimer's disease models demonstrate that SUL-138 is blood-brain barrier permeable, rescues synaptic plasticity and memory deficits, reduces amyloid-beta plaque load, and shifts mitochondrial metabolism toward fatty acid oxidation. It has also shown potential in treating renal ischemia/reperfusion injury, chronic obstructive pulmonary disease (COPD), and diabetic kidney damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SUL-138.